Kidney Cancer Research Summit

High levels of CD163-positive TAMs and exhausted CD8-positive TILs could potentially affect efficacy results in metastatic RCC by reprogramming TAMs.

KIM-1 levels have shown the ability to predict therapeutic benefit in patients with renal cell carcinoma.

Ritesh R. Kotecha, MD, discusses the rationale for targeting ENPP3 in clear cell renal cell carcinoma.

Findings from the KEYNOTE-B61 trial demonstrate antitumor activity across histologic subtypes, including those with papillary and chromophobe disease.

Karie Danielle Keera Runcie, MD, discusses treatment challenges after progression on adjuvant therapy and the potential role for zanzalintinib in renal cell carcinoma.

Treatment with belzutifan increased the time without progression or toxicity vs everolimus in patients with advanced RCC.

Metastasis-directed radiotherapy without systemic therapy demonstrated an improved safety profile vs immunotherapy and tyrosine kinase inhibitors.

Thomas Powles, MD, discusses results from a Q-TWiST analysis of belzutifan vs everolimus in previously treated advanced renal cell carcinoma.

Marc Machaalani, MD, discusses retrospective findings from a multi-platform analysis evaluating circulating KIM-1 as a biomarker in metastatic RCC.

Research supports the use of novel CAR T-cell therapy targeting CAIX and CD70 for the treatment of patients with advanced ccRCC.

Belzutifan generated superior efficacy and safety outcomes vs everolimus across prespecified subgroups of patients with previously treated advanced ccRCC.

Treatment with single-agent abemaciclib (Verzenio) did not demonstrate clinically meaningful activity in heavily treated patients with metastatic clear cell renal cell carcinoma.

Fianlimab plus cemiplimab produced durable responses in heavily pretreated advanced clear cell renal cell carcinoma.

Most patients included in the post-hoc pooled analysis who were treated with belzutifan experienced an all-cause adverse effect.

Karl Semaan, MD, MSc, discusses the utility of liquid biopsy epigenomic profiling for the detection of sarcomatoid renal cell carcinoma.

Bradley McGregor, MD, discusses findings from a phase 1b study of abemaciclib in clear cell renal cell carcinoma.

Laurence Albiges, MD, PhD, discusses research evaluating treatments for subtypes of non–clear cell renal cell carcinoma.

Real-world treatment patterns demonstrated that similar OS outcomes occurred for patients with renal cell carcinoma who received TKI- and immunotherapy-based regimens.

Toni K. Choueiri, MD, discusses the phase 3 TiNivo-2 study in pretreated advanced renal cell carcinoma.

Neil J. Shah, MBBS, discusses unmet needs for patients with RCC receiving immune-oncology–based combinations in the frontline setting.

Using an AI tool for the collection and analysis of patient data may enhance the accuracy of outcome predictions and help personalize treatment plans.

Nivolumab plus ipilimumab may generate positive long-term outcomes in patients with advanced renal cell carcinoma regardless of IMDC risk status.

Tian Zhang, MD, discusses unanswered questions regarding molecular drivers of kidney cancer that the OPTIC RCC trial aims to answer, next steps with this research, and the potential benefits of receiving systemic therapy prior to undergoing cytoreductive nephrectomy for patients with metastatic renal cell carcinoma.

Raquibul Hannan, MD, PhD, discusses the benefits of using stereotactic radiation in patients with localized RCC who are unfit for surgery, research findings indicating improved outcomes in patients who received radiation for metastatic disease, and how this radiation technique may work in concert with systemic therapy.

Patients with synchronous metastatic renal cell carcinoma who received first-line immunotherapy had worse survival outcomes compared with those with metachronous metastatic renal cell carcinoma.

The investigation of treatment regimens featuring antibody-drug conjugates or radiotherapeutics are part of the ongoing wave of research in renal cell carcinoma.

The combination of lenvatinib and pembrolizumab continued to show clinical activity in patients with metastatic renal cell carcinoma, including in subsets of patients who had received or were naïve to checkpoint inhibitors.

Higher levels of baseline TCR clonality in peripheral blood mononuclear cells (PBMCs) and baseline IgG1 fraction in PBMCs and tumor tissue were identified in an institutional cohort of samples from patient with metastatic renal cell carcinoma.